Sinovac Biotech Ltd. released positive data from a Phase II clinical trial of its pandemic flu (H5N1) vaccine. In the stratified, randomized, double-blind test, the top two dosage levels of Sinovac’s vaccine met the EMEA evaluation standards for seasonal flu vaccines. The trial did not discover any safety problems. Sinovac said it would use the Phase II results of the whole viron vaccine to determine dosing levels for the Phase III tests. More details...

Stock symbol: (AMEX: SVA)